Consistent with a specific effect of gefitinib on the EGFR, Erbitux, a monoclonal antibody specifically targeting the EGFR, similarly induces FGFR2 and FGFR3 expression in the same NSCLC cell lines that are responsive to gefitinib (Figure 1C). The gene discussed is FGFR3; the disease is non-small cell lung carcinoma.